Press release from Companies

Publicerat: 2023-01-20 09:00:00

Calmark Sweden AB: Calmark reconsiders its China strategy to focus on distributor cooperation

Calmark Sweden AB (publ) today announces a rethinking of the China strategy, in view of the current global context and the growing politicization of the Chinese business environment. The Wuxi subsidiary, which was foreseen to serve as the basis of a Joint Venture, will be dissolved; as in the rest of the world, the sales strategy in China will instead be based on distributor cooperation. Calmark’s subsidiary in Hong Kong will remain, henceforth forming the hub of the Chinese market activities.

International investments in China are decreasing in favour of markets such as for example India and Vietnam. Like many other companies, Calmark is now reconsidering its planned investments in China. 

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20-01-2023 09:00 CET.

For more information about Calmark Sweden AB, please contact:

Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50

E-post: camilla.arneving@calmark.se

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Läs mer hos Cision
Läs mer om Calmark Sweden AB